AUPQ167599A0 - Inhibitor of osteoclast precursor formation - Google Patents

Inhibitor of osteoclast precursor formation

Info

Publication number
AUPQ167599A0
AUPQ167599A0 AUPQ1675A AUPQ167599A AUPQ167599A0 AU PQ167599 A0 AUPQ167599 A0 AU PQ167599A0 AU PQ1675 A AUPQ1675 A AU PQ1675A AU PQ167599 A AUPQ167599 A AU PQ167599A AU PQ167599 A0 AUPQ167599 A0 AU PQ167599A0
Authority
AU
Australia
Prior art keywords
inhibitor
osteoclast precursor
precursor formation
formation
osteoclast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPQ1675A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Vincents Institute of Medical Research
Original Assignee
St Vincents Institute of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Vincents Institute of Medical Research filed Critical St Vincents Institute of Medical Research
Priority to AUPQ1675A priority Critical patent/AUPQ167599A0/en
Publication of AUPQ167599A0 publication Critical patent/AUPQ167599A0/en
Priority to PCT/AU2000/000864 priority patent/WO2001005964A1/en
Priority to AU57975/00A priority patent/AU780470B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
AUPQ1675A 1999-07-19 1999-07-19 Inhibitor of osteoclast precursor formation Abandoned AUPQ167599A0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AUPQ1675A AUPQ167599A0 (en) 1999-07-19 1999-07-19 Inhibitor of osteoclast precursor formation
PCT/AU2000/000864 WO2001005964A1 (en) 1999-07-19 2000-07-19 Inhibitor of osteoclast precursor formation
AU57975/00A AU780470B2 (en) 1999-07-19 2000-07-19 Inhibitor of osteoclast precursor formation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPQ1675A AUPQ167599A0 (en) 1999-07-19 1999-07-19 Inhibitor of osteoclast precursor formation

Publications (1)

Publication Number Publication Date
AUPQ167599A0 true AUPQ167599A0 (en) 1999-08-12

Family

ID=3815859

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPQ1675A Abandoned AUPQ167599A0 (en) 1999-07-19 1999-07-19 Inhibitor of osteoclast precursor formation

Country Status (2)

Country Link
AU (1) AUPQ167599A0 (en)
WO (1) WO2001005964A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2513905A1 (en) 2003-01-31 2004-08-19 Albor Biologics, Inc. Immune regulation based on the targeting of early activation molecules
WO2012000994A1 (en) * 2010-06-29 2012-01-05 C.N.R.S. Llt-1 antibodies with new functional properties

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
JPH1057071A (en) * 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd New dna and production of protein using the same
AU5901598A (en) * 1996-12-20 1998-07-17 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors

Also Published As

Publication number Publication date
WO2001005964A1 (en) 2001-01-25

Similar Documents

Publication Publication Date Title
AU6762400A (en) Inhibitors of factor xa
AU5283800A (en) Inhibitors of factor xa
AU5158100A (en) Inhibitors of factor xa
AU2001266068A1 (en) Treatment of mineral substrates
AU5155500A (en) Inhibitors of factor xa
AU3857300A (en) Inhibitors of factor xa
AU2557500A (en) Methods of making compounds
AU6111000A (en) Inhibitors of viral helcase
AU5283600A (en) Inhibitors of factor xa
AU1488501A (en) Methods of inhibiting metastasis
AU7354900A (en) Inhibitors of prenyl-protein transferase
AU2274101A (en) Inhibitors of prenyl-protein transferase
AU2002219175A1 (en) Crystalline forms of cerivastatin sodium
AU2002306734A1 (en) Inhibitors of plasmepsins
AU2252101A (en) New synthesis of SPLA2 inhibitors
AU2002222933A1 (en) Inhibitors of factor xa
AU2373600A (en) Novel spla2 inhibitors
AU5673099A (en) Inhibitors of amyloid formation
AU5433699A (en) Spacing of tiles
AUPQ167599A0 (en) Inhibitor of osteoclast precursor formation
AU8005100A (en) Inhibitors of neuraminidases
AU2050001A (en) Synthesis of indole-containing spla2 inhibitors
AU6769900A (en) Formation of nanometer-scale structures
AU7887100A (en) Corrosion inhibitor
EP1215193A3 (en) Production of 2-hydrocarbyl-2-adamantyl acrylate compounds

Legal Events

Date Code Title Description
NAA1 Application designating australia and claiming priority from australian document

Ref document number: 5797500

Country of ref document: AU